Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Chugai Seiyaku Kabushiki Kaisha patents


Recent patent applications related to Chugai Seiyaku Kabushiki Kaisha. Chugai Seiyaku Kabushiki Kaisha is listed as an Agent/Assignee. Note: Chugai Seiyaku Kabushiki Kaisha may have other listings under different names/spellings. We're not affiliated with Chugai Seiyaku Kabushiki Kaisha, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Chugai Seiyaku Kabushiki Kaisha-related inventors


Therapeutic agent for chronic arthritides diseases of childhood-related diseases

A therapeutic agent for chronic arthritides diseases of childhood-related diseases, for example chronic arthritides diseases of childhood, still's disease and the like, comprising an interleukin-6 (il-6) antagonist as an active ingredient.. . ... Chugai Seiyaku Kabushiki Kaisha

B cell activation inhibitor, and therapeutic agent for autoimmune diseases

The inventors found that b cell activation is suppressed by tgf-β3 produced by lag3+ treg. They also discovered a b cell activation suppressor which contains tgf-β3 or a molecule having a tgf-β3 function, and a therapeutic agent for autoimmune diseases.. ... Chugai Seiyaku Kabushiki Kaisha

Novel therapeutic agent for a lung disease and/or method for screening for the same

Provided are a therapeutic and/or prophylactic agent for a lung disease and a method for screening for the therapeutic and/or prophylactic agent. Provided are a therapeutic and/or prophylactic agent for a lung disease comprising an arid5a inhibitor as an active ingredient and a method for screening for the therapeutic and/or prophylactic agent.. ... Chugai Seiyaku Kabushiki Kaisha

Antiplexin a1 agonist antibody

Provided is a novel anti-plexin-a1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.. ... Chugai Seiyaku Kabushiki Kaisha

Non-human animal having human cd3 gene substituted for endogenous cd3 gene

The present invention provides genetically modified non-human animals which are deficient in at least one or more types of cd3 genes selected from the group consisting of endogenous cd3ε, cd3δ, and cd3γ in its genome and functionally express at least one or more types of human cd3 genes selected from the group consisting of human cd3ϵ, cd3δ, and cd3γ. In the genetically modified non-human animals of the present invention, mature t cell differentiation and production can take place, and immunocompetent cells including t cells can exert their functions. ... Chugai Seiyaku Kabushiki Kaisha

Therapeutic agent for mental illness comprising il-6 inhibitor as active ingredient

The present invention provides a novel therapeutic agent for mental illness. The therapeutic agent for mental illness comprises an il-6 inhibitor as an active ingredient.. ... Chugai Seiyaku Kabushiki Kaisha

Combined use of immune activators

The present invention is based on the finding that combined use of a multispecific antibody comprising: (1) a cancer-specific antigen-binding domain, (2) a cd3-binding domain, and (3) a domain comprising an fc region having decreased fcγ receptor-binding activity with a tumor necrosis factor (tnf) receptor superfamily agonist antibody can reduce side effects such as liver injury observed when the agonist antibody is prescribed alone, and achieve effective therapeutic effects.. . ... Chugai Seiyaku Kabushiki Kaisha

Gpc3-targeting therapeutic agent which is administered to patient for whom the gpc3-targeting therapeutic agent is effective

The present invention provides a method for determining the efficacy of a gpc3-targeting therapeutic agent for a liver cancer patient and a gpc3-targeting therapeutic agent or a preparation which is to be administered to a patient for whom it has been determined that the gpc3-targeting therapeutic agent is effective. The present invention provides, for example, a method for determining that a gpc3-targeting therapeutic agent is effective when the expression level of gpc3 per tumor cell is a predetermined value, and a gpc3-targeting therapeutic agent or a preparation which is to be administered to a patient for whom it has been determined that the gpc3-targeting therapeutic agent is effective.. ... Chugai Seiyaku Kabushiki Kaisha

Polypeptide modification method for purifying polypeptide multimers

The present invention provides efficient methods based on alteration of the protein a-binding ability, for producing or purifying multispecific antibodies having the activity of binding to two or more types of antigens to high purity through a protein a-based purification step alone. The methods of the present invention for producing or purifying multispecific antibodies which feature altering amino acid residues of antibody heavy chain constant region and/or variable region. ... Chugai Seiyaku Kabushiki Kaisha

Heterodimerized polypeptide

The present inventors produced a heterodimerized polypeptide having an fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an fc region with improved fc region function compared to that of a homodimer in which the fc region is composed of only the first polypeptide or only the second polypeptide by conventional technology.. . ... Chugai Seiyaku Kabushiki Kaisha

Diagnosis and treatment of cancer using anti-itm2a antibody

Disclosed is a monoclonal antibody binding to an itm2a protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as ewing's sarcoma, t cell leukemia, t cell lymphoma, acute myeloid leukemia, b cell tumor, and multiple myeloma. ... Chugai Seiyaku Kabushiki Kaisha

Method for determining application of novel therapy to multiple sclerosis (ms) patient

According to the present invention, the therapeutic effect of an il-6 inhibitor on ms was found to be predictable by using as indicators the amount of plasmablasts and/or the indicator of change in immature plasmablasts (amount of immature plasmablasts or amount of follicular helper t cells) in ms patients with a large amount of plasmablasts. Furthermore, il-6 inhibitors were found to be effective against ms in which plasmablasts occur at high levels and in which the indicator of change in immature plasmablasts is high. ... Chugai Seiyaku Kabushiki Kaisha

Composition for treating il-6-related diseases

The present invention provides a pharmaceutical composition for treating il-6-related diseases containing an il-6 inhibitor as an active ingredient, wherein the pharmaceutical composition is routinely administered after a short-interval dosing period where the same dose as the routine dose is administered at a shorter interval than the routine dosing interval.. . ... Chugai Seiyaku Kabushiki Kaisha

Method of modifying isoelectric point of antibody via amino acid substitution in cdr

The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (cdr). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. ... Chugai Seiyaku Kabushiki Kaisha

05/17/18 / #20180136195

Method for screening for cancer therapeutic agent

The invention aims to provide a method of screening for a therapeutic drug for cancer as a molecular-targeted drug targeting some protein from a number of candidate target proteins, without identifying the true target protein. In particular, the invention provides a method of screening for a therapeutic drug for cancer, including (i) a step of expressing an exogenous cell regulatory factor in a target cancer cell under contact or no contact with a test substance, (ii) a step of confirming change in the cancer cell, and (iii) a step of selecting the test substance as a therapeutic drug for cancer when the change of cancer cell increased under contact with the test substance as compared to no contact therewith.. ... Chugai Seiyaku Kabushiki Kaisha

05/17/18 / #20180133375

Pre-filled syringe formulation with needle, which is equipped with syringe cap

The purpose of the present invention is to provide a pre-filled syringe formulation with staked needle, which contains an antibody at a high concentration and can be produced on an industrial scale in a simple manner without causing clogging. A pre-filled syringe formulation with staked needle, in which a protein solution is packed. ... Chugai Seiyaku Kabushiki Kaisha

05/10/18 / #20180127761

Modified aminoacyl-trna synthetase and use thereof

The present invention provides modified aminoacyl-trna synthetases (arss) having increased reactivity with n-methyl amino acids compared to natural aminoacyl-trna synthetases. The modified aminoacyl-trna synthetases according to the present invention can aminoacylate trnas with their corresponding n-methyl-substituted amino acids such as n-methyl-phenylalanine, n-methyl-valine, n-methyl-serine, n-methyl-threonine, n-methyl-tryptophan, and n-methyl-leucine more efficiently than natural aminoacyl-trna synthetases. ... Chugai Seiyaku Kabushiki Kaisha

05/10/18 / #20180125972

Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion

A multiple antigen-binding molecule fusion molecule containing a multiple antigen-binding molecule (α) having an immune cell antigen-binding region and a cancer antigen-binding region, a cancer tissue-specific protease-cleavable linker (β), and a masking molecule (γ) containing a polypeptide having the amino acid sequence qdgne, in which the multiple antigen-binding molecule (α) and the masking molecule (γ) are linked via the cancer tissue-specific protease-cleavable linker (β).. . ... Chugai Seiyaku Kabushiki Kaisha

03/22/18 / #20180079817

Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising il-31 antagonist as active ingredient

In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an il-31 antagonist as an active ingredient, wherein the il-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.. . ... Chugai Seiyaku Kabushiki Kaisha

03/01/18 / #20180057607

Method for producing polypeptide hetero-oligomer

It is intended to provide a method for efficiently and stably producing a heteromultimer by incubating homo variants of plural types of heavy chain constant region-containing polypeptides differing in antigen-binding activity under a reducing condition that reorganize the inter-polypeptide disulfide bond between cysteine residues outside of core hinge regions. A feature of the production method of the present invention is that amino acid residues in the core hinge regions do not form any disulfide bond.. ... Chugai Seiyaku Kabushiki Kaisha

02/22/18 / #20180051307

Methods for producing polypeptides by regulating polypeptide association

In the course of the present invention, it was discovered that one could regulate association between polypeptides by modifying amino acid residues that form the interface during the association to amino acids carrying the same type of charge. In this context, the present invention enables efficient formation of heterologous molecules. ... Chugai Seiyaku Kabushiki Kaisha

02/22/18 / #20180051090

Process of production with controlled copper ions

The present invention provides a method of cell culture comprising adding a cell-containing seed medium to an initial medium and starting to culture the cell in the initial medium, wherein the initial medium has an organism-derived culture medium additive added thereto and the amount of the c-terminal amidated species in the produced protein is controlled by the copper content of the initial medium at the start of cell culture.. . ... Chugai Seiyaku Kabushiki Kaisha

01/18/18 / #20180016576

Novel therapeutic agent for septicemia, and a method for screening for same

The present invention provides a therapeutic agent for sepsis and/or septic shock and a method for screening for the therapeutic agent. The present invention relates to a therapeutic agent for sepsis and/or septic shock comprising an arid5a inhibitor as an active ingredient. ... Chugai Seiyaku Kabushiki Kaisha

01/18/18 / #20180016327

A combination of two or more anti-c5 antibodies and methods of use

The present invention provides a combination of two or more isolated or purified anti-c5 antibodies, wherein the isolated or purified anti-c5 antibodies bind to an epitope within the beta chain or alpha chain of c5 and wherein the isolated or purified anti-c5 antibodies to be combined do not compete with each other for binding to the epitope. Methods of using the combination for treating an individual having a complement-mediated disease or condition which involves excessive or uncontrolled activation of c5, or for enhancing the clearance of c5 from plasma in an individual, are also provided.. ... Chugai Seiyaku Kabushiki Kaisha

01/11/18 / #20180011114

Method for measuring reactivity of fviii

The inventors produced substances that neutralize the activity of a bispecific antibody having an activity of functionally substituting for fviii, and undertook the construction of methods for measuring the reactivity of fviii that can ensure accuracy even in the presence of this bispecific antibody. As a result, the inventors discovered that in aptt-based one-stage clotting assay, fviii activity in the plasma of a hemophilia a patient can be evaluated accurately, and also that in aptt-based bethesda assay, fviii inhibitor titer in the plasma of a hemophilia a patient carrying a fviii inhibitor can be evaluated accurately.. ... Chugai Seiyaku Kabushiki Kaisha

01/04/18 / #20180002443

Antibody substituting for function of blood coagulation factor viii

The present inventors produced a variety of bispecific antibodies that specifically bind to both f. Ix/f. ... Chugai Seiyaku Kabushiki Kaisha

01/04/18 / #20180002415

Anti-c5 antibodies and methods of use

An objective of the invention is to provide anti-c5 antibodies and methods of using the same. The invention provides anti-c5 antibodies and methods of using the same. ... Chugai Seiyaku Kabushiki Kaisha

01/04/18 / #20180002396

Novel hemopoietin receptor protein, nr10

The inventors succeeded in isolating a novel hemopoietin receptor gene (nr10) using a sequence predicted from the extracted motif conserved in the amino acid sequences of known hemopoietin receptors. It was expected that two forms of nr10 exists, a transmembrane type and soluble form. ... Chugai Seiyaku Kabushiki Kaisha

01/04/18 / #20180000779

Combination drug

The present invention relates to a drug that is for treating or preventing cancer, that is effective in the treatment of cancer, and that comprises a combination of an alk inhibitor and a vegf inhibitor. The present invention also relates to a method for treating or preventing cancer and a method for inhibiting tumor growth.. ... Chugai Seiyaku Kabushiki Kaisha

12/21/17 / #20170362304

Method for measuring viscosity of protein solution

The inventors discovered that viscosity of a protein solution can be estimated by measuring the apparent particle size or apparent molecular weight by a small angle x-ray scattering (saxs) method or x-ray solution scattering method, which enables measurement of small amounts of samples, and then correlating those measurement results with viscosity of the protein solution.. . ... Chugai Seiyaku Kabushiki Kaisha

11/30/17 / #20170342154

Modified antibody constant region

The present inventors succeeded in improving the antibody constant region to have increased stability under acid conditions, reduced heterogeneity originated from disulfide bonds in the hinge region, reduced heterogeneity originated from the h chain c terminus, and increased stability at high concentrations as well as in discovering novel constant region sequences having reduced fcγ receptor-binding, while minimizing the generation of novel t-cell epitope peptides. As a result, the present inventors successfully discovered antibody constant regions with improved physicochemical properties (stability and homogeneity), immunogenicity, safety, and pharmacokinetics.. ... Chugai Seiyaku Kabushiki Kaisha

11/30/17 / #20170342133

Sc(fv)2 site-directed mutant

To solve the above-mentioned problems, the present inventors introduced site-specific mutations into sc(fv)2 and examined the stabilizing effects on sc(fv)2. As a result, they succeeded for the first time in significantly increasing the tm value of sc(fv)2 by amino acid substitutions. ... Chugai Seiyaku Kabushiki Kaisha

10/05/17 / #20170283483

Methods of modifying antibodies for purification of bispecific antibodies

The present inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column based on the difference in isoelectric points between the h chains of two types of antibodies, wherein the difference is introduced by modifying the amino acids present on the surface of the antibody variable regions of two types of antibodies that constitute a bispecific antibody. Furthermore, the inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column by linking respective antigen binding sites (heavy chain variable regions) to the antibody constant regions having different isoelectric points, and then coexpressing these antibodies.. ... Chugai Seiyaku Kabushiki Kaisha

09/28/17 / #20170275376

Antibody capable of neutralizing substance having activity alternative to function of coagulation factor viii (fviii)

The present inventors attempted to produce antibodies that neutralize the activity of a substance having an activity of functionally substituting for fviii to be used for the method of measuring the reactivity of fviii in the presence of a substance having an activity of functionally substituting for fviii. As a result, the inventors discovered that by using the produced antibodies, fviii activity in the plasma of a hemophilia a patient can be evaluated accurately by one-stage clotting assay based on aptt, and also that fviii inhibitor titer in the plasma of a hemophilia a patient carrying a fviii inhibitor can be evaluated accurately by bethesda assay based on aptt.. ... Chugai Seiyaku Kabushiki Kaisha

09/28/17 / #20170275351

Method for production of antibody

The present invention provides a method of producing a recombinant antibody efficiently and at low cost. Disclosed is a method of producing an antibody or a fragment thereof, comprising allowing a cell to produce the antibody or the fragment, wherein the cell contains a larger number of copies of an exogenous dna encoding the light chain or a fragment thereof of the antibody than the number of copies contained in the cell of an exogenous dna encoding the heavy chain or a fragment thereof of the antibody. ... Chugai Seiyaku Kabushiki Kaisha

09/28/17 / #20170275332

Polypeptide modification method for purifying polypeptide multimers

The present invention provides efficient methods based on alteration of the protein a-binding ability, for producing or purifying multispecific antibodies having the activity of binding to two or more types of antigens to high purity through a protein a-based purification step alone. The methods of the present invention for producing or purifying multispecific antibodies which feature altering amino acid residues of antibody heavy chain constant region and/or variable region. ... Chugai Seiyaku Kabushiki Kaisha

09/21/17 / #20170267783

Cytotoxicity-inducing therapeutic agent

Novel multi specific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having t-cell receptor complex-binding activity, were discovered. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce novel pharmaceutical compositions for treating or preventing various cancers.. ... Chugai Seiyaku Kabushiki Kaisha

09/07/17 / #20170253663

Methods for treating a disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii

The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor ix and/or activated blood coagulation factor ix and blood coagulation factor x and/or activated blood coagulation factor x according to a given dosage regimen, diseases that develop and/or progress due to a decrease or deficiency in the activity of blood coagulation factor viii and/or activated blood coagulation factor viii can be prevented and/or treated more effectively.. . ... Chugai Seiyaku Kabushiki Kaisha

08/17/17 / #20170233462

Antibody against secreted n-terminal peptide of gpc3 present in blood or c-terminal peptide of gpc3

Disclosed is an antibody against a secreted form of gpc3 capable of detecting a secreted form of glypican 3 (gpc3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. ... Chugai Seiyaku Kabushiki Kaisha

08/03/17 / #20170219607

Method for identifying epitope on protein

. . In one aspect, the present invention provides, for example, an improved method for identifying an epitope on a protein, comprising the following steps: (a) contacting a major histocompatibility complex (mhc molecule)-expressing cell differentiated from a stem cell or a progenitor cell derived therefrom with a target protein; (b) isolating a complex of a peptide contained in the target protein and the mhc molecule from the mhc molecule-expressing cell; and (c) eluting the peptide from the complex and identifying the peptide.. . ... Chugai Seiyaku Kabushiki Kaisha

08/03/17 / #20170217927

Amorphous form of tetracyclic compound

An amorphous form of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile and a solid dispersion containing the amorphous form can be used extremely advantageously as drugs for oral administration.. . ... Chugai Seiyaku Kabushiki Kaisha

07/13/17 / #20170197039

Syringe cap, syringe with needle, and prefilled syringe formulation

Provided is a syringe cap including a projection extending in the circumferential direction of a cap body, wherein the projection includes an apex located radially outward of the cap body from the outer circumferential surface of the cap body, a first inclined surface having a starting end located at the apex and having a terminal end located at a position on the side closer to the proximal end of the cap body than the starting end is, and a second inclined surface having a starting end located at the apex and on the outer circumferential surface of the cap body having a terminal end located at a position on the side closer to the distal end of the cap body than the starting end is, on the outer circumferential surface of the cap body, and the shortest distance from the starting end to the terminal end of the first inclined surface is smaller than the shortest distance from the starting end to the terminal end of the second inclined surface.. . ... Chugai Seiyaku Kabushiki Kaisha

05/11/17 / #20170129950

Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient

The inventors successfully produced anti-epiregulin antibodies showing cross-species reactivity between cynomolgus monkey (non-human animals) and human, anti-epiregulin antibodies with suppressed chemical degradation, anti-epiregulin antibodies with lowered isoelectric point, anti-epiregulin antibodies with increased thermal denaturation midpoint temperature, and anti-epiregulin antibodies with reduced amount of aggregate by performing appropriate amino acid residue substitutions in the variable-region sequences of the humanized ep27 antibody which inhibits growth of cancer cells by exhibiting cytotoxic activity and neutralizing activity against human epiregulin-expressing cells.. . ... Chugai Seiyaku Kabushiki Kaisha

05/04/17 / #20170121412

Anti-il-6 receptor antibody

The present inventors succeeded in discovering specific amino acid mutations in the variable region, framework region, and constant region of tocilizumab, and this enables to reduce immunogenicity risk and the heterogeneity originated from disulfide bonds in the hinge region, as well as to improve antigen binding activity, pharmacokinetics, stability under acidic conditions, and stability in high concentration preparations.. . ... Chugai Seiyaku Kabushiki Kaisha

05/04/17 / #20170119781

Pharmaceutical composition comprising non-ionic surfactants

The present invention relates to a pharmaceutical composition comprising poorly soluble compounds such as bsc class ii or iv kinase inhibitors, a process for the preparation thereof and its use in the treatment of diseases, in particular cancer, further particularly in non-small lung cancer.. . ... Chugai Seiyaku Kabushiki Kaisha

04/27/17 / #20170112930

Stable protein-containing preparation containing argininamide or analogous compound thereof

. . Addition of argininamide or valinamide to a highly concentrated antibody solution was found to lead to remarkable stabilization, in particular, stabilization against photostress.. . ... Chugai Seiyaku Kabushiki Kaisha

03/23/17 / #20170081306

Novel crystal of tetracyclic compound

The present invention relates to type ii and type iii crystals of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile that is a pharmaceutically useful novel crystal.. . ... Chugai Seiyaku Kabushiki Kaisha

02/09/17 / #20170035773

Preparation containing tetracyclic compound at high dose

An improved solubility of a pharmaceutical composition or formulation containing a large amount of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile or a salt thereof can be achieved by forming granules of the compound or salt thereof and allowing the granules to be present together with a disintegrating agent.. . ... Chugai Seiyaku Kabushiki Kaisha

01/26/17 / #20170022293

Nucleic acid encoding bispecific antibodies

Various bispecific antibodies that specifically bind to both blood coagulation factor ix/activated blood coagulation factor ix and blood coagulation factor x and functionally substitute for the cofactor function of blood coagulation factor viii, that is, the function to promote activation of blood coagulation factor x by activated blood coagulation factor ix, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor viii were successfully discovered.. ... Chugai Seiyaku Kabushiki Kaisha

01/26/17 / #20170022287

Immunoactivating antigen-binding molecule

It was discovered that the use of an antigen-binding molecule having a cancer-specific antigen-binding domain, and a tnf superfamily-binding domain or a tnf receptor superfamily-binding domain enables agonist activity against a factor belonging to the tnf superfamily or the tnf receptor superfamily to be exhibited only in the presence of cancer-specific antigen-expressing cells, thus leading to activation of immune cells and thereby maintain anti-tumor activity while avoiding side effects such as hepatotoxicity. It was also discovered that concomitant use of the antigen-binding molecule with an antigen-binding molecule having a cancer-specific antigen-binding domain and a t cell receptor complex-binding domain can avoid side effects while increasing the anti-tumor activity.. ... Chugai Seiyaku Kabushiki Kaisha

01/26/17 / #20170022278

Preventive or therapeutic agent for sensitized t cell-mediated diseases comprising il-6 antagonist as an active ingredient

A preventive or therapeutic agent for sensitized t cell-mediated diseases comprising an interleukin-6 (il-6) antagonist, for example an antibody directed against il-6 receptor, an antibody directed against il-6, an antibody directed against gp130, and the like.. . ... Chugai Seiyaku Kabushiki Kaisha

01/26/17 / #20170022270

Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities

The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human fcrn under an acidic ph range condition; (ii) of binding under a neutral ph range condition to human fc receptor stronger than native human igg, and (iii) that its antigen-binding activity alters according to the ion concentration.. . ... Chugai Seiyaku Kabushiki Kaisha








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Chugai Seiyaku Kabushiki Kaisha in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Chugai Seiyaku Kabushiki Kaisha with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###